此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During Rhinoplasty

2026年10月13日 更新者:Sibel Onen Ozdemir、Hitit University

Effects of Different Mean Arterial Pressure Targets on Ocular Perfusion and OCTA-Derived Optic Nerve Head Microvasculature During Controlled Hypotension in Rhinoplasty: A Prospective Randomized Controlled Trial

This randomized controlled trial aims to evaluate the effects of two different mean arterial pressure (MAP) targets during controlled hypotension on ocular perfusion and optic nerve head microvasculature in patients undergoing elective rhinoplasty or septorhinoplasty.

A total of 60 patients will be randomized in a 1:1 ratio to a target MAP of either 50-60 mmHg or 60-70 mmHg during general anesthesia. Intraocular pressure (IOP) will be measured at predefined perioperative time points, and estimated ocular perfusion pressure (OPP) will be calculated using simultaneous MAP and IOP measurements. Optical coherence tomography angiography (OCTA) will be performed preoperatively and postoperatively to assess changes in peripapillary, optic nerve head, and macular microvascular parameters.

The primary objective is to compare changes in peripapillary vessel density between the two MAP target groups. Secondary objectives include evaluating changes in optic nerve head microvasculature, intraoperative OPP and IOP, and the relationships between the depth and duration of hypotension and OCTA-derived microvascular changes.

研究概览

详细说明

Controlled hypotension is commonly used during rhinoplasty to reduce intraoperative bleeding and improve surgical field visibility. However, reductions in mean arterial pressure (MAP) may also decrease ocular perfusion pressure (OPP), particularly when accompanied by changes in intraocular pressure (IOP). Although perioperative ischemic optic neuropathy is rare, hypotension and other factors that reduce tissue perfusion have been reported as potential contributors to perioperative visual complications. The effects of different controlled hypotension targets on ocular perfusion and optic nerve head microvasculature during rhinoplasty remain insufficiently characterized.

This prospective randomized controlled trial will include 60 patients aged 18-50 years with American Society of Anesthesiologists (ASA) physical status I-II who are scheduled for elective rhinoplasty or septorhinoplasty under general anesthesia. Participants will be randomized in a 1:1 ratio using computer-generated block randomization to one of two intraoperative controlled hypotension strategies: a target MAP of 50-60 mmHg or a target MAP of 60-70 mmHg. Participants and the ophthalmologist performing the postoperative OCTA assessment will be blinded to group allocation, whereas the attending anesthesiologist and surgeon will not be blinded.

All patients will receive standardized general anesthesia. MAP and other standard monitoring parameters will be continuously monitored. IOP will be measured noninvasively in the same eye using tonometry at predefined perioperative time points: before induction of anesthesia, after endotracheal intubation, after achieving the target MAP, 15 minutes after establishment of controlled hypotension, every 30 minutes thereafter during maintained hypotension, at the end of surgery, and during the early post-extubation period. MAP will be recorded simultaneously with each IOP measurement, and estimated OPP will be calculated as MAP minus IOP.

Optical coherence tomography angiography (OCTA) will be performed using the same device before surgery and during postoperative follow-up. Preoperative OCTA will be obtained 1-7 days before surgery, and postoperative assessments will be performed within 24-72 hours, at 1 week, and at 1 month. OCTA-derived parameters will include peripapillary vessel density, optic nerve head vessel density, and superficial and deep macular vascular density.

The primary outcome is the change in peripapillary vessel density from the preoperative measurement to the early postoperative assessment. Secondary outcomes include changes in optic nerve head and macular microvascular parameters, minimum intraoperative estimated OPP, maximum change in IOP, and the relationships between the depth and duration of controlled hypotension and postoperative OCTA-derived microvascular changes.

The study is designed to determine whether different MAP targets used during controlled hypotension are associated with different patterns of ocular perfusion and subclinical optic nerve head microvascular change. The study is not designed to determine the incidence of perioperative ischemic optic neuropathy or other rare postoperative visual complications.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 18-50 years
  • Scheduled for elective rhinoplasty or septorhinoplasty
  • American Society of Anesthesiologists (ASA) physical status I-II
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • History of glaucoma, retinal disease, optic neuropathy, or other significant ophthalmologic disease
  • Previous ocular surgery
  • High myopia
  • Uncontrolled hypertension, diabetes mellitus, or other serious systemic disease
  • ASA physical status III or higher
  • Development of severe intraoperative hemodynamic instability
  • Massive intraoperative bleeding
  • Inadequate OCTA image quality for analysis
  • Pregnancy
  • Refusal to participate or withdrawal of consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Lower MAP Target (50-60 mmHg)

Participants assigned to this group will undergo controlled hypotension during general anesthesia with a target mean arterial pressure (MAP) of 50-60 mmHg. Hemodynamic parameters will be continuously monitored, and the anesthetic regimen will be titrated to maintain MAP within the assigned target range while ensuring clinical safety.

Controlled hypotension will be maintained with a target mean arterial pressure (MAP) of 50-60 mmHg during general anesthesia. MAP will be continuously monitored, and anesthetic management will be titrated as clinically appropriate to maintain the assigned target range.

有源比较器:Higher MAP Target (60-70 mmHg)

Participants assigned to this group will undergo controlled hypotension during general anesthesia with a target mean arterial pressure (MAP) of 60-70 mmHg. Hemodynamic parameters will be continuously monitored, and the anesthetic regimen will be titrated to maintain MAP within the assigned target range while ensuring clinical safety.

Controlled hypotension will be maintained with a target mean arterial pressure (MAP) of 60-70 mmHg during general anesthesia. MAP will be continuously monitored, and anesthetic management will be titrated as clinically appropriate to maintain the assigned target range.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Peripapillary Vessel Density at 24-72 Hours After Surgery
大体时间:Preoperative baseline (1-7 days before surgery) to 24-72 hours after surgery

Change in peripapillary vessel density measured by optical coherence tomography angiography (OCTA) from the preoperative baseline to 24-72 hours after surgery. Vessel density will be quantified using the same OCTA device and scanning protocol for all assessments. The primary comparison will be the difference in change from baseline between the two randomized MAP target groups.

Preoperative baseline (1-7 days before surgery) to 24-72 hours after surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月20日

初级完成 (估计的)

2026年12月1日

研究完成 (估计的)

2026年12月15日

研究注册日期

首次提交

2026年9月16日

首先提交符合 QC 标准的

2026年9月16日

首次发布 (实际的)

2026年9月21日

研究记录更新

最后更新发布 (实际的)

2026年10月14日

上次提交的符合 QC 标准的更新

2026年10月13日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

De-identified individual participant data that underlie the results reported in the published article may be made available upon reasonable request to the corresponding author. Data will be shared for scientifically sound research purposes, subject to approval by the study investigators and in accordance with applicable ethical and institutional requirements. No directly identifiable participant information will be shared.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅